By Puyaan Singh and Bhanvi Satija (Reuters) -AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug ...
AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...
AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.
Shares in AbbVie slumped by double digits Monday after the company disclosed its psychiatric medicine emraclidine didn’t best ...
The other possibility is that M1 agonism is required for muscarinic drugs to work and this ... The best-case scenario would ...
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.
was the main focus AbbVie's acquisition of Cerevel, which closed earlier this year. The setback is a potential plus for Bristol Myers Squibb, which in September won Food and Drug Administration ...
Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.
We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...
Stocks rose to record highs again Monday, while bitcoin hit all-time highs of its own above $86,000, as the election-fueled rally continues.
The report includes market projections, regulatory information, and updates on new products and technologies. It also ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...